| Rachel Mae Chiara, MS CCC-SLP | |
|
276 Race St, Belvidere, NJ 07823-1616 | |
| (908) 235-2987 | |
| Not Available |
| Full Name | Rachel Mae Chiara |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 276 Race St, Belvidere, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609380641 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 41YS0077540 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Mae Chiara, MS CCC-SLP 276 Race St, Belvidere, NJ 07823-1616 Ph: (908) 235-2987 | Rachel Mae Chiara, MS CCC-SLP 276 Race St, Belvidere, NJ 07823-1616 Ph: (908) 235-2987 |
News Archive
VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.
Eppendorf is proud to announce a new addition to the BioBLU Single-use Vessel Adaptor Kit portfolio. The BioBLU 5c and 14c Adaptor Kits allow BioBLU 5c and 14c Single-use vessels to be used on and controlled by Sartorius® BioStat® B-DCU-II controllers (Heat Blanket configuration only).
BIOTRONIK AG, a European manufacturer of therapy solutions for vascular intervention, has announced the international full market release of the innovative Pulsar-18 stent for treatment of long lesions in the superficial femoral and infrapopliteal arteries. Pulsar-18 is unique in the market, representing an advance in technology that further reinforces the company's position as a leader in providing high quality technologies for patients with peripheral vascular disease.
Bio2 Technologies, Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Fusion Implant system for interphalangeal fusion, fracture repair and osteotomies of the toes, fingers and other small bones in the presence of appropriate immobilization.
› Verified 4 days ago
Mrs. Sandra L Simone, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 168 Summerfield Rd, Belvidere, NJ 07823 Phone: 201-874-8861 | |
Catherine Grace Deehan, MA SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Brookfield Dr, Belvidere, NJ 07823 Phone: 908-475-5556 |